Login / Signup

Promiscuity of in Vitro Secondary Pharmacology Assays and Implications for Lead Optimization Strategies.

Dean G BrownGraham F SmithHeike J Wobst
Published in: Journal of medicinal chemistry (2019)
We conducted an analysis on screening data generated from 1445 compounds against a panel of 130 enzymes, ion channels, and receptors to assess secondary pharmacological risks. Hit rates of these targets as well as physicochemical properties for those hits were evaluated. A majority of targets yielded hits with higher clogP, molecular weight, and more basic character than inactive compounds. Although most targets favored lipophilic hits, the average clogP of hits at a given target did not correlate with its hit rate. Furthermore, a matched pair analysis was completed to determine structural changes that impacted off-target activities. A correlation of binding assays used in this analysis illustrated that some pharmacologically related binding assays are highly correlative and may be substituted for a smaller set of surrogate assays.
Keyphrases
  • high throughput
  • electronic health record
  • risk assessment
  • binding protein
  • big data
  • data analysis
  • human health
  • transcription factor
  • drug induced